GO:0006568 obsolete L-tryptophan metabolic process

GO:0006568, obsolete L-tryptophan metabolic process, is a retired Gene Ontology biological process term that was defined as the chemical reactions and pathways involving tryptophan, the chiral amino acid 2-amino-3-(1H-indol-3-yl)propanoic acid. The term was widely used in early GO annotations to capture any process that consumed or produced L-tryptophan, including its biosynthesis, catabolism, and incorporation into proteins and small-molecule neurotransmitters. Because the definition was intentionally broad, it grouped together mechanistically distinct pathways such as the kynurenine pathway, the serotonin pathway, and the melatonin pathway under a single node. The GO Consortium later obsoleted the term to avoid annotation ambiguity and to force curators to use more precise child terms. Despite its obsolete status, GO:0006568 remains a useful search anchor because many legacy datasets, publications, and bioinformatics pipelines still contain annotations to this identifier. Researchers who encounter GO:0006568 in enrichment results should therefore treat it as a historical pointer to L-tryptophan metabolism rather than as a currently valid ontology class. The clinical relevance of L-tryptophan metabolism is well established: urinary 5-hydroxyindoleacetic acid (5-HIAA), the main serotonin metabolite, is measured to diagnose and monitor carcinoid tumors and other neuroendocrine neoplasms, and pre-analytical factors such as diet and sampling method strongly influence its interpretation. This article reviews the biology that was historically captured by GO:0006568, the genes and enzymes involved, the diseases linked to tryptophan metabolic dysfunction, and the CRISPR-based methods that can be used to study these pathways in a publication-ready manner.

In plain terms, GO:0006568 was a Gene Ontology biological process class that described all chemical reactions and pathways involving L-tryptophan, the chiral amino acid 2-amino-3-(1H-indol-3-yl)propanoic acid. The term was intended to cover any enzymatic step that consumed, modified, or produced L-tryptophan, including its biosynthesis from chorismate, its catabolism through the kynurenine pathway, its hydroxylation to 5-hydroxytryptophan, and its decarboxylation to serotonin. Because this definition was too broad and overlapped with more specific terms, GO:0006568 is now marked as obsolete. The official QuickGO record lists synonyms tryptophan metabolic process and tryptophan metabolism, and the ontology aspect is biological_process. When interpreting legacy annotations, the term should be understood as a historical grouping of L-tryptophan-dependent biochemistry rather than as a currently maintained ontology node.

Although GO:0006568 is obsolete, understanding the biology it represented remains important because L-tryptophan metabolism sits at the intersection of neurotransmission, immune regulation, and cancer biology. L-tryptophan is the sole precursor for serotonin and melatonin, which regulate mood, sleep, and circadian rhythms, and it is also the substrate for the kynurenine pathway, which produces neuroactive metabolites and NAD+. Dysregulation of these pathways has been implicated in neuroendocrine tumors, mood disorders, and immune escape in cancer. The measurement of urinary 5-HIAA, a downstream metabolite of the serotonin branch of L-tryptophan metabolism, is a standard clinical test for carcinoid syndrome and related neuroendocrine neoplasms, and its interpretation requires careful attention to pre-analytical factors such as dietary tryptophan intake and sampling conditions. For researchers, legacy annotations to GO:0006568 often appear in gene enrichment analyses, and misinterpreting them as a single coherent pathway can lead to incorrect biological conclusions. This makes it essential to map obsolete annotations to active child terms and to validate pathway involvement experimentally using CRISPR-based models.

The following genes and enzymes were historically associated with L-tryptophan metabolism and are relevant to the biology formerly captured by GO:0006568.

The processes historically grouped under GO:0006568 are regulated at multiple levels. Enzyme expression is controlled by transcription factors and cytokines; for example, interferon-gamma induces IDO1, shifting L-tryptophan flux toward the kynurenine pathway. Substrate availability, transport across membranes by SLC7A5/SLC3A2, and feedback inhibition by downstream metabolites also regulate flux. In the serotonin branch, TPH1 and TPH2 are regulated by phosphorylation and by tryptophan availability, while AANAT activity in the pineal gland is controlled by circadian signals and adrenergic input. Because GO:0006568 is obsolete, current GO annotations use more specific terms such as tryptophan catabolic process and serotonin biosynthetic process to capture these regulatory mechanisms. Researchers should consult QuickGO for the active child terms that replace GO:0006568 in their specific pathway of interest.

Neuroendocrine tumors, including carcinoid tumors, can secrete serotonin and other vasoactive substances, leading to carcinoid syndrome. Urinary 5-HIAA, the main metabolite of serotonin produced via the L-tryptophan/serotonin pathway, is a key biomarker for diagnosis and monitoring of these tumors. Pre-analytical factors such as dietary tryptophan and serotonin intake, sampling method, and storage conditions can significantly affect 5-HIAA results, and recommendations for standardized urinary sampling have been published to improve clinical interpretation. Genes such as TPH1 and DDC, which were historically annotated to GO:0006568, are directly relevant to this disease context.

IDO1 and TDO2, enzymes that catalyze the first step of the kynurenine branch of L-tryptophan metabolism, are often overexpressed in tumors and can suppress antitumor immunity by depleting L-tryptophan and producing immunosuppressive kynurenine metabolites. Inhibitors of IDO1 and TDO2 have been tested in clinical trials as cancer immunotherapy agents. Because these enzymes were historically annotated under GO:0006568, legacy datasets may group them with serotonin pathway enzymes, and researchers should use active GO child terms to distinguish immune-related from neurotransmitter-related functions.

Alterations in L-tryptophan metabolism have been implicated in mood disorders, schizophrenia, and neurodegenerative diseases. The serotonin branch influences mood and anxiety, while the kynurenine branch produces neuroactive metabolites such as quinolinic acid and kynurenic acid that can modulate glutamatergic signaling and neuroinflammation. TPH2, KMO, and KYNU are among the genes studied in these contexts. Because GO:0006568 is obsolete, modern studies use specific GO terms for serotonin biosynthesis, kynurenine catabolism, and related processes to link genes to disease mechanisms.

Melatonin, produced from serotonin via AANAT and ASMT, regulates circadian rhythms and sleep. Dysregulation of melatonin synthesis has been studied in sleep disorders, shift work, and aging. L-tryptophan availability also affects NAD+ synthesis through the kynurenine pathway, linking tryptophan metabolism to cellular redox balance and metabolic health. These connections illustrate why the broad biology formerly captured by GO:0006568 remains relevant to multiple disease areas.

Targeted metabolomics using LC-MS/MS can quantify L-tryptophan, serotonin, kynurenine, 5-HIAA, and other pathway intermediates in cells, media, and biological fluids. Urinary 5-HIAA measurement is a clinically validated test for carcinoid tumors and other neuroendocrine neoplasms, and standardized sampling recommendations have been published to reduce pre-analytical variability. These methods are essential for validating CRISPR models of tryptophan-metabolizing enzymes.

Genome-wide CRISPR knockout or activation screens can identify genes that regulate L-tryptophan dependence, serotonin production, or kynurenine pathway flux. Cells are cultured under high or low L-tryptophan conditions, and sgRNA enrichment or depletion is measured by next-generation sequencing. This approach can uncover novel regulators of the pathways formerly grouped under GO:0006568.

RNA-seq can measure expression of TPH1, TPH2, IDO1, TDO2, KMO, KYNU, AANAT, ASMT, and other tryptophan-metabolizing genes. Enrichment analysis may return obsolete GO:0006568 annotations from legacy databases, so researchers should map these to active child terms such as tryptophan catabolic process and serotonin biosynthetic process before drawing conclusions.

Proteomic profiling can quantify enzyme abundance, while activity assays measure conversion of L-tryptophan to downstream products. For example, IDO1 activity can be measured by kynurenine production, and TPH activity can be measured by 5-hydroxytryptophan formation. These assays complement CRISPR knockout and knock-in models by linking genotype to enzymatic function.

Researchers studying obsolete L-tryptophan metabolic process-related genes often need to determine whether a candidate gene is causally involved in serotonin, melatonin, or kynurenine pathway biology. EDITGENE provides CRISPR-based cell model services that enable knockout, point-mutation, knock-in, and overexpression studies, as well as library screening and bioinformatics support, to help teams move from legacy GO annotations to experimentally validated mechanisms.

GO:0006568, obsolete L-tryptophan metabolic process, is a retired Gene Ontology term that historically grouped all chemical reactions and pathways involving L-tryptophan. Although it is no longer an active ontology class, the biology it represented remains central to serotonin and melatonin signaling, kynurenine pathway immunology, and clinical biomarkers such as urinary 5-HIAA. Researchers who encounter GO:0006568 in legacy datasets should map it to active child terms and validate pathway involvement using CRISPR-based models. EDITGENE provides the knockout, point-mutation, knock-in, overexpression, and screening services needed to move from annotation to mechanism.